Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsChing‐Yao Yang, Chong‐Jen Yu, Jih‐Hsiang Lee et al.|European Journal of Cancer|2019Cited by 92
Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung CancerChia‐Chi Hsu, James Chih‐Hsin Yang, Bin-Chi Liao et al.|Journal of Thoracic Oncology|2019Cited by 84
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|The Oncologist|2020Cited by 25
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|Journal of the Formosan Medical Association|2024Cited by 5
Abstract 4752: Exon-16-skipping HER2 contributes to osimertinib-resistance through Src-independent manner in <i>EGFR</i> L858R/T790M-positive non-small-cell lung cancerChia‐Chi Hsu, Bin-Chi Liao, Wei‐Yu Liao et al.|Cancer Research|2019Cited by 1